, Volume 14, Issue 1, pp 1–16 | Cite as

SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo

  • Wan-Ru Chao
  • Khalid Amin
  • Yihui Shi
  • Peter Hobbs
  • Mas Tanabe
  • Mary Tanga
  • Ling Jong
  • Nathan Collins
  • Richard Peters
  • Keith Laderoute
  • Dominic Dinh
  • Dawn Yean
  • Carol Hou
  • Barbara Sato
  • Carsten Alt
  • Lidia Sambucetti
Original Paper


Angiogenesis is one of the major processes controlling growth and metastasis of tumors. Angiogenesis inhibitors have been targeted for the treatment of various cancers for more than 2 decades. We have developed a novel class of steroidal compounds aimed at blocking the angiogenic process in cancerous tissues. Our lead compound, SR16388, is a potent antiangiogenic agent with binding affinity to estrogen receptor-α (ER-α) and -β (ER-β) at the nanomolar range. This compound inhibited the proliferation of human microvascular endothelial cells (HMVEC) and various types of human cancer cells in vitro. SR16388 inhibited embryonic angiogenesis as measured in the chick chorioallantoic membrane (CAM) assay. The blood vessel density in the CAM was greatly reduced after the embryos were treated with 3 μg/CAM of SR16388 for 24 h. SR16388 at a dose of 2 μM prevented tube formation in Matrigel after HMVEC cells were treated for 8 h. In a modified Boyden chamber assay, SR16388 inhibited the migration of HMVECs by 80% at 500 nM. Using a novel in vivo Fibrin Z-chamber model, we demonstrated that SR16388 at a single daily oral dose of 3 mg/kg for 12 days significantly inhibited the granulation tissue (GT) thickness and the microvessel density of the GT as compared to control. More importantly, SR16388 down-regulated the pro-angiogenic transcription factors, hypoxia inducible factor 1α (HIF-1α) and signal transducer and activator of transcription 3 (STAT3) in non-small cell lung cancer (NSCLC) cells. Together, these effects of SR16388 can lead to the reduction of vascularization and tumor growth in vivo.


Angiogenesis Chick chorioallantoic membrane Fibrin Z-chamber model Hypoxia inducible factor-1α Signal transducer and activator of transcription 3 Tube formation Tumor xenograft Vascular endothelial growth factor 


  1. 1.
    Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27–31CrossRefPubMedGoogle Scholar
  2. 2.
    Folkman J, Shing Y (1992) Angiogenesis. J Bio Chem 267:10931–10934Google Scholar
  3. 3.
    Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787CrossRefPubMedGoogle Scholar
  4. 4.
    Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248CrossRefPubMedGoogle Scholar
  5. 5.
    Rosen LS (2005) VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 10:382–391CrossRefPubMedGoogle Scholar
  6. 6.
    Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328–335CrossRefPubMedGoogle Scholar
  7. 7.
    Takahashi Y, Kitadai Y, Bucana CD et al (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon Cancer. Cancer Res 55:3964–3968PubMedGoogle Scholar
  8. 8.
    Boocock CA, Charnock-Jones DS, Sharkey AM et al (1995) Expression of vascular endothelial growth factor and its receptor flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87(7):506–516CrossRefPubMedGoogle Scholar
  9. 9.
    Zeng G, Taylor SM, McColm JR et al (2007) Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. Blood 109:1345–1352CrossRefPubMedGoogle Scholar
  10. 10.
    Kliche S, Waltenberger J (2001) VEGF receptor signaling and endothelial function. IUBMB Life 52:61–66CrossRefPubMedGoogle Scholar
  11. 11.
    Claesson-Welch L (2003) Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 31:20–24CrossRefGoogle Scholar
  12. 12.
    Shojaei F, Ferrara N (2007) Antiangiogensis to treat cancer and intraocular neovascular disorders. Lab Invest 87:227–230CrossRefPubMedGoogle Scholar
  13. 13.
    Folkman J, Kalluri R (2003) Tumor angiogenesis. In: Kufe DW, Pollock RE, Weichselbaum RR et al (eds) Cancer medicine. B.C. Decker Inc., Hamilton, pp 161–194Google Scholar
  14. 14.
    Satchi-Fainaro R, Mamluk R, Wang L et al (2005) Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7:251–261CrossRefPubMedGoogle Scholar
  15. 15.
    Huang ZH, Fan YF, Xia H et al (2003) Effects of TNP-470 on proliferation and apoptosis in human colon cancer xenografts in nude mice. World J Gastroenterol 9(2):281–283PubMedGoogle Scholar
  16. 16.
    Huang JH, Fischer JS, New T et al (2004) TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther 3(3):335–343PubMedGoogle Scholar
  17. 17.
    Benny O, Fainaru O, Adini A et al (2008) An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 26(7):799–807CrossRefPubMedGoogle Scholar
  18. 18.
    Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4):266–276CrossRefPubMedGoogle Scholar
  19. 19.
    Jung JE, Kim HS, Lee CS et al (2007) Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cells. Carcinogenesis 28(8):1780–1787CrossRefPubMedGoogle Scholar
  20. 20.
    Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-induced factor-1. Semin Cancer Biol 19:12–16CrossRefPubMedGoogle Scholar
  21. 21.
    Semenza GL (2007) Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 102:840–847CrossRefPubMedGoogle Scholar
  22. 22.
    Simiantonaki N, Jayasinghe C, Michel-Schmidt R et al (2008) Hypoxia-induced epithelial VEGFD-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol 32:585–592PubMedGoogle Scholar
  23. 23.
    Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9(4):777–794CrossRefPubMedGoogle Scholar
  24. 24.
    Niu G, Briggs J, Deng J et al (2008) Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1α RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res 6(7):1099–1105CrossRefPubMedGoogle Scholar
  25. 25.
    Kimbro KS, Simons JW (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13:739–749CrossRefPubMedGoogle Scholar
  26. 26.
    LaVallee TM, Burke PA, Swartz GM et al (2008) Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 7(6):1472–1482CrossRefPubMedGoogle Scholar
  27. 27.
    Moser C, Lang SA, Mori A et al (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1 alpha and STAT3 activity in human hepatocellular carcinoma (HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 8:206CrossRefPubMedGoogle Scholar
  28. 28.
    Siddiquee KAZ, Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and haematological tumors. Cell Res 18:254–267CrossRefGoogle Scholar
  29. 29.
    Brantley EC, Nabors LB, Gillespie GY et al (2008) Loss of protein inhibitors of activated STAT3 expression in glioblatoma multiform tumors: implications for STAT3 activation and gene expression. Clin Cancer Res 14:4694–4704CrossRefPubMedGoogle Scholar
  30. 30.
    Niu G, Wright KL, Huang M et al (2002) Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000–2008CrossRefPubMedGoogle Scholar
  31. 31.
    Chen Z, Han ZC (2008) STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28(2):185–200CrossRefPubMedGoogle Scholar
  32. 32.
    Schaefer LK, Ren Z, Fuller GN et al (2002) Constitutive activation of STAT3α in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor 2 (VEGFR2). Oncogene 21:2058–2065CrossRefPubMedGoogle Scholar
  33. 33.
    Kortylewski M, Yu H (2008) Role of STAT3 in suppressing anti-tumor immunity. Curr Opin Immunol 20(2):228–233CrossRefPubMedGoogle Scholar
  34. 34.
    Kim ES, Hong SY, Lee HK et al (2008) Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol Rep 20:1321–1327PubMedGoogle Scholar
  35. 35.
    Heimberger AB, Priebe W (2008) Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov 3(3):179–188CrossRefPubMedGoogle Scholar
  36. 36.
    Timofeeva OA, Gaponenko V, Lockett SJ et al (2007) Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol 2(12):799–809CrossRefPubMedGoogle Scholar
  37. 37.
    Singh RP, Raina K, Deep G et al (2009) Silibinin suppress growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase ½ and inhibition of signal transducers and activators of transcription signaling. Clin Cancer Res 15(2):613–621CrossRefPubMedGoogle Scholar
  38. 38.
    Tyagi A, Singh RP, Ramasamy K et al (2009) Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kB and signal transducers and activators of transcription 3. Cancer Prev Res 2(1):74–83CrossRefGoogle Scholar
  39. 39.
    Leong H, Mathur PS, Greene GL (2009) Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat 117:505–515CrossRefPubMedGoogle Scholar
  40. 40.
    Nemenoff RA, Winn RA (2005) Role of nuclear receptors in lung tumourigenesis. Eur J Cancer 41:2561–2568CrossRefPubMedGoogle Scholar
  41. 41.
    Sola B, Renoir JM (2006) Antiestrogenic therapies in solid cancers and multiple myeloma. Curr Mol Med 6:359–368CrossRefPubMedGoogle Scholar
  42. 42.
    Hall JM, McDonnell DP (1999) The estrogen receptor beta-osiform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140:5566–5578CrossRefPubMedGoogle Scholar
  43. 43.
    Harris HA (2007) Estrogen receptor-β: recent lessons from in vivo studies. Mol Endocrinol 21(1):1–13CrossRefPubMedGoogle Scholar
  44. 44.
    Horvath LG, Henshall SM, Lee C-S et al (2001) Frequent loss of estrogen receptor-β expression in prostate cancer. Cancer Res 61:5331–5335PubMedGoogle Scholar
  45. 45.
    Stettner M, Kaulfub S, Burfeind P et al (2007) The relevance of estrogen receptor-β expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 6(10):2626–2633CrossRefPubMedGoogle Scholar
  46. 46.
    Imamov O, Lopatkin NA, Gustafsson J-K (2004) Estrogen receptor β in prostate cancer. N Engl J Med 351(26):2773–2774CrossRefPubMedGoogle Scholar
  47. 47.
    Pravettoni A, Mornai O, Martini PGV et al (2007) Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol 263:46–54CrossRefPubMedGoogle Scholar
  48. 48.
    Stabile LP, Davis AL, Gubish CT et al (2002) Human non-small cell lung tumors and cell derived from normal lung express both estrogen receptors (alpha) and (beta) and show biological response to estrogen. Cancer Res 62(7):2141–2150PubMedGoogle Scholar
  49. 49.
    Marquez-Garban DC, Chen HW, Fishbein MC et al (2007) Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72:135–143CrossRefPubMedGoogle Scholar
  50. 50.
    Ali G, Donati V, Loggini B et al (2008) Different estrogen receptors expression in distinct histologic subtypes of lung adenocarcinoma. Human Pathol 39:1465–1473CrossRefGoogle Scholar
  51. 51.
    Skov BG, Fisher BM, Pappot H (2008) Oestrogen receptor β over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59:88–94CrossRefPubMedGoogle Scholar
  52. 52.
    Omoto Y, Kobayashi Y, Nishida K et al (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285:340–347CrossRefPubMedGoogle Scholar
  53. 53.
    Treon SP, Teoh G, Urashima M et al (1998) Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 92:1749–1757PubMedGoogle Scholar
  54. 54.
    Otsuki T, Yamada O, Kurebayshi J et al (2000) Estrogen receptors in human myeloma cells. Cancer Res 60:1434–1441PubMedGoogle Scholar
  55. 55.
    Sola B, Renoir JM (2007) Estrogenic or anti estrogenic therapies for multiple myeloma? Mol Cancer 6:59. doi: 10.1186/1476-4598-6-59 CrossRefPubMedGoogle Scholar
  56. 56.
    Gagliardi A, Collins DC (1993) Inhibition of angiogenesis by antiestrogens. Cancer Res 53:533–535PubMedGoogle Scholar
  57. 57.
    Lindner DJ, Borden EC (1997) Effects of tamoxifen and interferon-β or the combination on tumor-induced angiogenesis. Int J Cancer 71:456–461CrossRefPubMedGoogle Scholar
  58. 58.
    Tanabe M, Peters R, Chao W-R et al (2000) Antiestrogenic steroids, and associated pharmaceutical compositions and methods of use. U.S. Patent 6,054,446 April 25 2000Google Scholar
  59. 59.
    Guo Y, Higazi AA, Arakelian A et al (2000) A peptide derived from the non-receptor-binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB 14:1400–1410CrossRefGoogle Scholar
  60. 60.
    Amin K, Li J, Chao W-R et al (2003) Dietary glycine inhibits angiogenesis during wound healing and tumor growth. Cancer Biol Ther 2(2):173–178PubMedGoogle Scholar
  61. 61.
    Ryan HE, Poloni M, McNulty W et al (2000) Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res 60:4010–4015PubMedGoogle Scholar
  62. 62.
    Murphy BJ, Sato BG, Dalton TP et al (2005) The metal-responsive transcription factor-1 contributes to HIF-1 activation during hypoxia stress. Biochem Biophys Res Commun 337:860–867CrossRefPubMedGoogle Scholar
  63. 63.
    Quesnelle KM, Boeham AL, Grandis JR (2007) STAT-mediated EGFR signaling in cancer. J Cell Biochem 102:311–319CrossRefPubMedGoogle Scholar
  64. 64.
    Gao SP, Mark KG, Leslie K et al (2007) Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117(12):3846–3856CrossRefPubMedGoogle Scholar
  65. 65.
    Gridelli C, Bareschino MA, Schettino C et al (2007) Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12:840–849CrossRefPubMedGoogle Scholar
  66. 66.
    Renoir JM, Bouclier C, Seguin A et al (2008) Antiestrogen-mediated cell cycle arrest and apoptosis induction in breast and multiple myeloma cells. J Mol Endocrinol 40:101–112CrossRefPubMedGoogle Scholar
  67. 67.
    Lonard DM, Smith CL (2002) Molecular perspectives on selective estrogen receptor modulators (SERM): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 67:15024CrossRefGoogle Scholar
  68. 68.
    Buzadar AU (2005) TAS-108: a novel steroidal antiestrogen. Clin Cancer Res 11:906s–908sGoogle Scholar
  69. 69.
    Kumagai Y, Fujita T, Ozaki M et al (2009) Safety, tolerability and pharmacokinetics of TAS-108, a novel anti-estrogen, in healthy post menopausal Japanese women: a phase I single oral dose study. Basic Clin Pharmacol Toxicol 104:352–359CrossRefPubMedGoogle Scholar
  70. 70.
    Eeullman SJ, Calaoagan JM, Sato BG et al (2010) A novel steroidal inhibitor of estrogen-related receptor alpha (ERR-alpha). Biochem Pharmacol 80:819–826CrossRefGoogle Scholar
  71. 71.
    Giguere V (2008) Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocrine Rev 29:677–696CrossRefGoogle Scholar
  72. 72.
    Tremblay AM, Giguere V (2007) The NR3B subgroup: an overview. Nucl Recept Signal 5:e009PubMedGoogle Scholar
  73. 73.
    Ao A, Wang H, Kamarajugadda S et al (2008) Involvement of estrogen-related receptors in transcriptional response to hypoxia and growth of solid tumors. Proc Natl Acad Sci USA 105:7821–7826CrossRefPubMedGoogle Scholar
  74. 74.
    Mak P, Leav I, Pursell B et al (2010) ER-β impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implication for Gleason grading. Cancer Cell 17(4):319–332CrossRefPubMedGoogle Scholar
  75. 75.
    Bookout AL, Jeong Y, Downes M et al (2006) Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789–799CrossRefPubMedGoogle Scholar
  76. 76.
    Lai JS, Brown LG, True LD (2004) Metastases of prostate cancer express estrogen receptor = beta. Urology 64(4):814–820CrossRefPubMedGoogle Scholar
  77. 77.
    Zhu X, Leave I, Leung YK et al (2004) Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol 164(6):2003–2012CrossRefPubMedGoogle Scholar
  78. 78.
    Kuba K, Matsumoto K, Date K (2000) HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60:6737–6743PubMedGoogle Scholar
  79. 79.
    Buettner R, Mora LB, Jove R (2002) Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8:945–954PubMedGoogle Scholar
  80. 80.
    Bromberg J, Darnell JE Jr (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468–2473CrossRefPubMedGoogle Scholar
  81. 81.
    Bartoli M, Plantt D, Lemtalsi T et al (2003) VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 17:1562–1564PubMedGoogle Scholar
  82. 82.
    Alas S, Bonavida B (2003) Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 9:316–326PubMedGoogle Scholar
  83. 83.
    Chen SH, Murphy DA, Lassoued W et al (2008) Activated STAT3 is a mediator and biomarker of VEGF endothelial activation. Cancer Biol Ther 7(12):1994–2003CrossRefPubMedGoogle Scholar
  84. 84.
    Yahata Y, Shirakata Y, Tokumaru S et al (2003) Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem 278:40026–40031CrossRefPubMedGoogle Scholar
  85. 85.
    Xu Q, Briggs J, Park S et al (2005) Targeting STAT3 blocks both HIF and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552–5560CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Wan-Ru Chao
    • 1
  • Khalid Amin
    • 2
  • Yihui Shi
    • 1
  • Peter Hobbs
    • 1
  • Mas Tanabe
    • 1
  • Mary Tanga
    • 1
  • Ling Jong
    • 1
  • Nathan Collins
    • 1
  • Richard Peters
    • 1
  • Keith Laderoute
    • 1
  • Dominic Dinh
    • 1
  • Dawn Yean
    • 3
  • Carol Hou
    • 1
  • Barbara Sato
    • 1
  • Carsten Alt
    • 1
  • Lidia Sambucetti
    • 1
  1. 1.Drug Discovery Department, Biosciences DivisionSRI InternationalMenlo ParkUSA
  2. 2.Department of Pathology and Laboratory MedicineUniversity of Kansas Medical CenterKansas CityUSA
  3. 3.Applied StemCell, Inc.SunnyvaleUSA

Personalised recommendations